CTI BioPharma Corp

NASDAQ:CTIC  
2.19
+0.03 (+1.39%)
Earnings Announcements

Cti Biopharma Reports Q4 Loss Per Share Of $0.20

Published: 03/17/2021 20:28 GMT
CTI BioPharma Corp (CTIC) - Cti Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results.
Q4 Loss per Share $0.20.
Expect Our Current Cash, Cash Equivalents and Short-term Investments Will Enable US to Fund Our Operations Into Q2 of 2021.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.23

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.22

More details on our Analysts Page.